Mika K. Poblete
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mika K. Poblete has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Audrey M. Putelo
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
38 shared publications - Cara N. Hatzinger
University of Virginia 1 Charlottesville, Virginia
38 shared publications - Melanie R. Rutkowski
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
38 shared publications - Mitchell T. McGinty
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
38 shared publications - Simona Bajgai
University of Virginia 2 Charlottesville
38 shared publications - Sree H. Kolli
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia
38 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Metabolic profiling of mammary gland and fecal mircobiome in mice with and without dysbiosis.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Metabolic profiling of mammary gland and fecal mircobiome in mice with and without dysbiosis.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Baseline characteristics of bile acid sequestrant (BAS) user and non-user groups.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Baseline characteristics of bile acid sequestrant (BAS) user and non-user groups.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Characterization of bile acid receptor and invasion, migration, and ECM remodeling-associated protein profiles of breast tumor cells.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Characterization of bile acid receptor and invasion, migration, and ECM remodeling-associated protein profiles of breast tumor cells.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Myeloid cell infiltration of lungs in early tumor-bearing mice with or without dysbiosis and treated or untreated with colesevelam.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Myeloid cell infiltration of lungs in early tumor-bearing mice with or without dysbiosis and treated or untreated with colesevelam.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Reagents and resources information.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Reagents and resources information.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Metastatic dissemination of breast tumor cells to multiple sites of metastasis at early and late tumor endpoints following bile acid supplementation.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Metastatic dissemination of breast tumor cells to multiple sites of metastasis at early and late tumor endpoints following bile acid supplementation.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Metabolic characterization of fecal microbiota transfer (FMT) model.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Metabolic characterization of fecal microbiota transfer (FMT) model.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Patient selection for Epic Cosmos survival analysis, supporting Tables 1 and 2.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Patient selection for Epic Cosmos survival analysis, supporting Tables 1 and 2.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Characterization of body composition and microbiome in mice with or without dysbiosis following treatment with colesevelam HCl.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Characterization of body composition and microbiome in mice with or without dysbiosis following treatment with colesevelam HCl.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Breast cancer is the most commonly diagnosed malignancy and a leading cause of cancer-related mortality. Hormone receptor–positive (HR+) tumors represent the most prevalent metastatic subtype, and early dissemination remains a major clinical challenge. Commensal dysbiosis, defined as an inflammatory gut microbiome with low biodiversity, promotes metastasis by inducing mammary gland inflammation. In this study, we investigated systemic mechanisms governing dysbiosis-induced metastasis. Metabolomic profiling revealed elevated primary bile acids (BA) in the dysbiotic fecal microbiome. Sequestration and supplementation approaches demonstrated that beyond driving metabolic disease and mammary gland inflammation, primary BAs orchestrated enhanced HR+ tumor dissemination via a prostaglandin E2 (PGE2)–dependent pathway. Analysis of The Cancer Genome Atlas showed that BA, insulin resistance, and PGE2 gene signatures are associated with reduced survival in patients with HR+ tumors. In complementary analyses using the Epic Cosmos electronic health record database, BA sequestrant use was associated with longer restricted mean survival time among patients with metastatic disease. Together, these findings reveal that commensal dysbiosis-associated loss of microbial BA metabolism elevates primary BAs and promotes HR+ metastatic progression through PGE2 signaling. Significance:Dysbiosis-induced bile acids drive systemic and mammary tissue-specific inflammation that promotes HR+ breast tumor metastasis, supporting the development of strategies targeting microbiome-derived metabolites to reduce metastatic risk in vulnerable populations.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Commensal Dysbiosis Alters Primary Bile Acid Signaling to Drive Mammary Gland Inflammation and Breast Tumor Dissemination
Breast cancer is the most commonly diagnosed malignancy and a leading cause of cancer-related mortality. Hormone receptor–positive (HR+) tumors represent the most prevalent metastatic subtype, and early dissemination remains a major clinical challenge. Commensal dysbiosis, defined as an inflammatory gut microbiome with low biodiversity, promotes metastasis by inducing mammary gland inflammation. In this study, we investigated systemic mechanisms governing dysbiosis-induced metastasis. Metabolomic profiling revealed elevated primary bile acids (BA) in the dysbiotic fecal microbiome. Sequestration and supplementation approaches demonstrated that beyond driving metabolic disease and mammary gland inflammation, primary BAs orchestrated enhanced HR+ tumor dissemination via a prostaglandin E2 (PGE2)–dependent pathway. Analysis of The Cancer Genome Atlas showed that BA, insulin resistance, and PGE2 gene signatures are associated with reduced survival in patients with HR+ tumors. In complementary analyses using the Epic Cosmos electronic health record database, BA sequestrant use was associated with longer restricted mean survival time among patients with metastatic disease. Together, these findings reveal that commensal dysbiosis-associated loss of microbial BA metabolism elevates primary BAs and promotes HR+ metastatic progression through PGE2 signaling. Significance:Dysbiosis-induced bile acids drive systemic and mammary tissue-specific inflammation that promotes HR+ breast tumor metastasis, supporting the development of strategies targeting microbiome-derived metabolites to reduce metastatic risk in vulnerable populations.